Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results